These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23133682)

  • 1. Fexinidazole: a potential new drug candidate for Chagas disease.
    Bahia MT; de Andrade IM; Martins TA; do Nascimento ÁF; Diniz Lde F; Caldas IS; Talvani A; Trunz BB; Torreele E; Ribeiro I
    PLoS Negl Trop Dis; 2012; 6(11):e1870. PubMed ID: 23133682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
    Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
    Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.
    Bahia MT; Nascimento AF; Mazzeti AL; Marques LF; Gonçalves KR; Mota LW; Diniz Lde F; Caldas IS; Talvani A; Shackleford DM; Koltun M; Saunders J; White KL; Scandale I; Charman SA; Chatelain E
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4362-70. PubMed ID: 24841257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
    Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
    Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
    Diniz LF; Mazzeti AL; Caldas IS; Ribeiro I; Bahia MT
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
    Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
    Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
    Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repurposing strategy against Trypanosoma cruzi infection: In vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy.
    Simões-Silva MR; De Araújo JS; Oliveira GM; Demarque KC; Peres RB; D'Almeida-Melo I; Batista DGJ; Da Silva CF; Cardoso-Santos C; Da Silva PB; Batista MM; Bahia MT; Soeiro MNC
    Biochem Pharmacol; 2017 Dec; 145():46-53. PubMed ID: 28870526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
    Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
    Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.
    Camandaroba EL; Reis EA; Gonçalves MS; Reis MG; Andrade SG
    Rev Soc Bras Med Trop; 2003; 36(2):201-9. PubMed ID: 12806455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.
    Veloso VM; Carneiro CM; Toledo MJ; Lana M; Chiari E; Tafuri WL; Bahia MT
    Mem Inst Oswaldo Cruz; 2001 Oct; 96(7):1005-11. PubMed ID: 11685270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
    Torreele E; Bourdin Trunz B; Tweats D; Kaiser M; Brun R; Mazué G; Bray MA; Pécoul B
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e923. PubMed ID: 21200426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial.
    Pinazo MJ; Forsyth C; Losada I; Esteban ET; García-Rodríguez M; Villegas ML; Molina I; Crespillo-Andújar C; Gállego M; Ballart C; Ramirez JC; Aden T; Hoerauf A; Pfarr K; Vaillant M; Marques T; Fernandes J; Blum B; Ribeiro I; Sosa-Estani S; Barreira F; Gascón J;
    Lancet Infect Dis; 2024 Apr; 24(4):395-403. PubMed ID: 38218194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoeba histolytica.
    Raether W; Seidenath H
    Ann Trop Med Parasitol; 1983 Feb; 77(1):13-26. PubMed ID: 6411009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.
    Torchelsen FKVDS; Silva TM; Milagre MM; Silva RR; Reis LES; Branquinho RT; Silva GN; de Lana M
    Parasitol Res; 2021 Apr; 120(4):1511-1517. PubMed ID: 33236174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
    Saraiva VB; Gibaldi D; Previato JO; Mendonça-Previato L; Bozza MT; Freire-De-Lima CG; Heise N
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3472-7. PubMed ID: 12384352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage.
    Francisco AF; Jayawardhana S; Lewis MD; White KL; Shackleford DM; Chen G; Saunders J; Osuna-Cabello M; Read KD; Charman SA; Chatelain E; Kelly JM
    Sci Rep; 2016 Oct; 6():35351. PubMed ID: 27748443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.